Business
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers
About this update from Newamsterdam Pharma Company N.v.
[{"type":"text","content":"Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers\nNAARDEN, the Netherlands and MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will present new clinical and preclinical data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society (EAS) 93rd Congress, taking place on May 4-7, 2025 in Glasgow, UK. Late-breaker oral presentation details are as follows: Title: Fixed-Dose Combination of Obicetrapib and Ezetimibe for LDL-C Reduction: A Phase 3 Randomized TrialSession Name: Late Breaker Session: ClinicalOral Presentation Date and Time: Wednesday, May 5, 2025, 12:00-12:15 PM BST (7:00-7:15 AM ET)Location: William Harvey Hall Title: Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular RiskSession Name: Late Breaker Session: ClinicalOral Presentation Date and Time: Wednesday, May 5, 2025, 12:15-12:30 PM BST (7:15-7:30 AM ET)Location: Will Harvey Hall Additional session details are as follows: Title: Obicetrapib Reduces Atherosclerosis and Vascular Inflammation, Mainly by Reducing Non-HDL Cholesterol, Improves Lesion Stability and Adds to the Beneficial Effects of EzetimibeSession Name: SaaG Session: Emerging Lipid-Lowering Strategies: Mechanisms, Pre-clinical Studies and OutcomesPresentation Date and Time: Monday, May 5, 2025, 1:58-2:05 PM BST (8:58-9:05 AM ET)Location: Station 7 Title: Obicetrapib Alone and in Combination with Ezetimibe Increases Reverse Cholesterol Transport and Does Not Affect VLDL ProductionSession Name: SaaG Session: Emerging Lipid-Lowering Strategies: Mechanisms, Pre-clinical Studies and OutcomesPresentation Date and Time: Monday, May 5, 2025, 2:05-2:12 PM BST (9:05-9:12 AM ET)Location: Station 7 Title: Low-Dose Obicetrapib Significantly Increases Concentrations of Lipophilic Antioxidants, ApoE, and S1P in HDL SubfractionsSession Name: S...